Lifeboat Foundation

A new project will see scientists use human brain stem cells on microchips to push the boundaries of artificial intelligence.

Facilitating Novel Health-Tech and Bio-Medical Innovations For Over 9 Million Veterans — Dr. Rachel Ramoni, Chief of R&D, U.S. Department of Veterans Affairs.

Dr. Rachel Ramoni, is the Chief Research and Development Officer of the United States Department of Veterans Affairs (VA), where she oversees their nationwide research enterprise, encompassing some 2000 active projects, at more than 100 sites, with a total budget of $2 billion in both direct VA support, and research funding from outside entities such as the National Institutes of Health, other federal agencies, and nonprofit and private organizations.

Continue reading “Dr. Rachel Ramoni, Chief R&D Officer, U.S. Dept. of Veterans Affairs (VA) — Facilitating Innovation” »

Excerpts from an enlightening interview / conversation conducted by Brian Kennedy with Matt Kaeberlein on the biology of aging.
The interview took place in November 2020 as the first one under the healthy longevity webinar series organized by Brian Kennedy from the National University of Singapure (NUS).

During the conversation, Matt Kaeberlein makes a nice description about what aging is, as well as about therapies, drugs and other interventions that, at least in animals of various kinds, manage to modulate (delay / reverse) the progress of aging.

Continue reading “Matt Kaeberlein on the biology of aging. Excerpts from an interview with Brian Kennedy” »

The human species has driven the planet’s biodiversity into an unprecedented decline, with as many as 1 million species at risk. Traditional conservation methods alone are struggling to offset the speed at which we’re losing species. Biotechnologies that have been developing in the wings are now being brought forward to potentially reverse the damage already done. Meet the scientist behind de-extinction.

#Moonshot #Science #BloombergQuicktake.
——-
Like this video? Subscribe: https://www.youtube.com/Bloomberg?sub_confirmation=1

Continue reading “What Happens If We Solve Extinction?” »

Harvard’s Capasso Group has scaled up the achromatic metalens to 2mm in diameter. That may not sound like much, but it is plenty for virtual reality contact lenses. The human pupil is 7mm at widest. These guys are going to beat Mojo Lens to the finish line for smart contact lenses.

Read the latest updates on coronavirus from Harvard University. For SEAS specific-updates, please visit SEAS & FAS Division of Science: Coronavirus FAQs.

Biochemical changes after going to space suggest that harm to cells’ energy-producing structures, called mitochondria, could explain astronauts’ health issues.

Jared Isaacman invites you to join the fight against childhood cancer, and possibly wind up with a seat on the first orbital flight by an all-civilian team of astronauts.

Research into a new drug that primes the immune system in the respiratory tract and is in development for COVID-19 shows it is also effective against rhinovirus.

Rhinovirus is the most common respiratory virus, the main cause of the common cold and is responsible for exacerbations of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease. In a study recently published in the European Respiratory Journal, the drug, known as INNA-X, is shown to be effective in a pre-clinical infection model and in human airway cells.

Treatment with INNA-X prior to infection with rhinovirus significantly reduced viral load and inhibited harmful inflammation.

When will the pandemic end? It’s the question hanging over just about everything since COVID-19 took over the world last year. The answer can be measured in vaccinations.

Bloomberg has built the biggest database of COVID-19 shots given around the world, with more than 108 million doses administered worldwide. U.S. science officials such as Anthony Fauci have suggested it will take 70% to 85% coverage of the population for things to return to normal. Bloomberg’s Vaccine Tracker shows that some countries are making far more rapid progress than others, using 75% coverage with a two-dose vaccine as a target.